Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pyratine is a topical skincare line featuring the active ingredient furfuryl tetrahydropyranyladenine (PRK-124), a synthetic, nature-identical plant cytokinin. Originally developed by Senetek PLC and later managed by Pyratine LLC, the compound is a second-generation cytokinin designed to treat inflammatory skin conditions and signs of photodamage. As a plant growth factor analog, it modulates cell senescence and inflammatory pathways, effectively reducing facial erythema (redness), inflammatory lesions, and hyperpigmentation. Clinical trials have demonstrated its efficacy in treating mild-to-moderate rosacea, inflammatory acne, atopic dermatitis, and melasma. Unlike many traditional topical treatments such as retinoids, Pyratine is non-irritating and helps repair the skin's moisture barrier, making it suitable for long-term use in patients with sensitive or compromised skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pyratine.